Rsv rna molecules and compositions for vaccination
AssigneeCureVac AG
InventorsJohannes LUTZ, Susanne RAUCH, Regina HEIDENREICH, Benjamin PETSCH
Life of this patent
Estimating the term…
Abstract
The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with Respiratory syncytial virus (RSV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.
Claims30
A purified mRNA molecule, said RNA molecule comprising:
- a) a 5′-cap structure comprising m7G;
- b) a heterologous 5′ untranslated region (UTR);
- c) at least one coding sequence encoding an antigenic RSV F protein having an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO:
- 4957, wherein said at least one coding sequence is at least 90% identical to the RNA sequence of SEQ ID NO:
- 4958;
- and
- d) at least one poly(A) sequence comprising 30 to 150 consecutive adenosine nucleotides.
Dependencies are inferred from the claim text.